Sugi Predict

Sugi Predict / Compounds / SCHEMBL7180834

SCHEMBL7180834

SCHEMBL7180834

Cc1cc(C(C)(C)C)cc(C)c1C(=O)P(=O)(C(=O)c1c(C(F)(F)F)cccc1C(F)(F)F)c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 1/20 0.37
▸ TAS2R14 Q9NYV8 2/20 0.35
▸ LMNA P02545 2/20 0.35
▸ HTT P42858 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ PTPN5 P54829 1/20 0.34
▸ KCNK9 Q9NPC2 2/20 0.34
▸ PGK1 P00558 1/20 0.34
▸ PGK2 P07205 1/20 0.34
▸ ACHE P22303 1/20 0.34
▸ TRPV1 Q8NER1 2/20 0.34
▸ GAA P10253 2/20 0.34
▸ KCNK3 O14649 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7185586 0.91 NPSR1 (0.41) NPSR1LMNAMEN1KMT2ACYP1A2
SCHEMBL7186785 0.90 LMNA (0.44) NPSR1TAS2R14LMNAHTTSMN1; SMN2
SCHEMBL7175290 0.88 ALDH1A1 (0.39) NPSR1TAS2R14LMNAKCNK9GAA
SCHEMBL7187514 0.88 LMNA (0.40) NPSR1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL7183900 0.87 MEN1 (0.39) NPSR1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL7182360 0.87 TP53 (0.39) NPSR1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL7179453 0.85 TAS2R14 (0.37) NPSR1TAS2R14LMNAHTTSMN1; SMN2
SCHEMBL7180917 0.85 TAS2R14 (0.39) NPSR1TAS2R14LMNAHTTSMN1; SMN2
SCHEMBL7181473 0.85 NPSR1 (0.39) NPSR1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL7180182 0.84 LMNA (0.40) LMNAMEN1KMT2ATSHRKCNK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 NPSR1 2669/4885TAS2R14 2184/4885LMNA 3241/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 NPSR1 3007/4885TAS2R14 2410/4885LMNA 3247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.